ADMA Biologics (ADMA) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADMA Hot Sheet
Join SI Premium – FREE
ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $141.1 million versus the consensus estimate of $138.12 million.
Reiterated FY2026 Revenue Guidance and Increased Adjusted Earnings Outlook
FY2026 total revenue expected to be at least $530 million
FY2026 Adjusted Net Income expected to be at least $180 million
FY2026 Adjusted EBITDA expected to be at least $275 million
For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- PureCycle Technologies, Inc. (PCT) Tops Q3 EPS by 25c
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
